- \n
- Delivered Year-over-Year Growth in Reported Revenue of +18.4% and Underlying Revenue of +3.8%, Driven by 14 Global Brands <\/i><\/b><\/li>\n
- Grew Reported Operating Profit of 248.6 Billion Yen ($2.2B) and Solid Underlying Core Operating Profit Margin of 30.5% While Increasing R&D Investments<\/i><\/b><\/li>\n
- Paid 242.9 Billion Yen Toward $2.2 Billion of Debt in Q1 and Company Expects to Pre-pay a Total of Approximately 450 Billion Yen (~$4.1B) of Debt in FY2021<\/i><\/b><\/li>\n
- Anticipated Inflection Year for the Pipeline with Five to Six Regulatory Submissions and Seven New Molecular Entities in Pivotal Studies by Fiscal Year-End <\/i><\/b><\/li>\n
- Confirms Full-year FY2021 Management Guidance and Forecast<\/i><\/b><\/li>\n<\/ul>\n
OSAKA, Japan–(BUSINESS WIRE<\/a>)–Takeda Pharmaceutical Company Limited (TOKYO:4502\/NYSE:TAK)<\/b> (\u201cTakeda\u201d) today announced financial results for the first quarter of fiscal year 2021 (period ended June 30, 2021). Based on the solid first-quarter results, the Company also confirmed its fiscal year 2021 management guidance and forecast. Fiscal year 2021 remains a year of inflection with Takeda positioned for topline acceleration and continued pipeline progress, including critical regulatory submissions, potential approvals and additional new molecular entities (NMEs) advancing in pivotal studies.\n<\/p>\n
Costa Saroukos, Chief Financial Officer, commented:
\n
<\/b>\u201cWith the Shire integration behind us and continued transformation over the last two years, we\u2019ve pivoted towards accelerating topline growth and investing in R&D to fuel our highly innovative pipeline. Takeda\u2019s first-quarter results demonstrate the continued strength of our 14 global brands and, with the business momentum from this strong start to our fiscal year, we remain on track towards our full-year management guidance.\u201d<\/i><\/p>\n\u201cFY2021 is an inflection year for our pipeline as we ramp up strategic R&D investments and the pipeline starts to deliver. We anticipate having five to six Wave 1 pipeline regulatory submissions by the end of this fiscal year, with the potential for five approvals by end of H1 FY2022. The resilience of Takeda\u2019s business model is a testament to our unwavering commitment to serving patients, our people and the planet. We are focused on discovering and delivering life-transforming treatments to people around the world to create and maximize long-term value for society.\u201d<\/i><\/p>\n
FINANCIAL AND BUSINESS HIGHLIGHTS<\/b><\/p>\n
Results for Q1 FY2021 Ended June 30, 2021<\/b><\/p>\n
- Grew Reported Operating Profit of 248.6 Billion Yen ($2.2B) and Solid Underlying Core Operating Profit Margin of 30.5% While Increasing R&D Investments<\/i><\/b><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210729006282\/en\/791321\/3\/logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n